Abstract
A 70-year-old man with asymptomatic proliferative diabetic retinopathy received a single intravitreal injection of bevacizumab (Avastin). One month following treatment there was complete resolution of new vessels.
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Diabetic Retinopathy / complications
-
Diabetic Retinopathy / drug therapy*
-
Fluorescein Angiography
-
Humans
-
Injections
-
Male
-
Optic Disk / blood supply*
-
Retinal Neovascularization / drug therapy*
-
Retinal Neovascularization / etiology
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / immunology
-
Vitreous Body
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab